Trial Outcomes & Findings for Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT NCT00678210)

Last Updated: 2012-12-19

Results Overview

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

197 participants

Primary outcome timeframe

Week 12

Results posted on

2012-12-19

Participant Flow

Participant milestones

Participant milestones
Measure	CP-690,550 2 mg CP-690,550 tablets equivalent to CP-690,550 2 milligram (mg) orally twice daily for 12 weeks.	CP-690,550 5 mg CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Overall Study STARTED	49	49	49	50
Overall Study COMPLETED	38	38	43	30
Overall Study NOT COMPLETED	11	11	6	20

Reasons for withdrawal

Reasons for withdrawal
Measure	CP-690,550 2 mg CP-690,550 tablets equivalent to CP-690,550 2 milligram (mg) orally twice daily for 12 weeks.	CP-690,550 5 mg CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Overall Study Adverse Event	1	2	3	3
Overall Study Lack of Efficacy	2	3	1	9
Overall Study Lost to Follow-up	4	2	0	1
Overall Study Withdrawal by Subject	3	4	1	7
Overall Study Other	1	0	1	0

Baseline Characteristics

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	CP-690,550 2 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.	Total n=197 Participants Total of all reporting groups
Age, Customized 18 to 44 years	23 participants n=5 Participants	25 participants n=7 Participants	28 participants n=5 Participants	20 participants n=4 Participants	96 participants n=21 Participants
Age, Customized 45 to 54 years	13 participants n=5 Participants	14 participants n=7 Participants	10 participants n=5 Participants	18 participants n=4 Participants	55 participants n=21 Participants
Age, Customized 54 to 64 years	9 participants n=5 Participants	9 participants n=7 Participants	6 participants n=5 Participants	10 participants n=4 Participants	34 participants n=21 Participants
Age, Customized Greater than or equal to 65 years	4 participants n=5 Participants	1 participants n=7 Participants	5 participants n=5 Participants	2 participants n=4 Participants	12 participants n=21 Participants
Sex: Female, Male Female	20 Participants n=5 Participants	20 Participants n=7 Participants	18 Participants n=5 Participants	14 Participants n=4 Participants	72 Participants n=21 Participants
Sex: Female, Male Male	29 Participants n=5 Participants	29 Participants n=7 Participants	31 Participants n=5 Participants	36 Participants n=4 Participants	125 Participants n=21 Participants

PRIMARY outcome

Timeframe: Week 12

Population: Full analysis set (FAS) included all randomized participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values were imputed using last observation carried forward (LOCF).

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12	25.00 percentage of participants	40.82 percentage of participants	66.67 percentage of participants	2.00 percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 14, 16

Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF for week 2, 4, 8, 12 and no imputation done for week 14, 16. n=participants evaluable for this measure at specified time points for each arm group respectively.

Physician global assessment of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the whole body according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. The score of 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 2 (n=48, 48, 48, 49)	8.33 percentage of participants	12.50 percentage of participants	16.67 percentage of participants	4.08 percentage of participants
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 12 (n=49, 49, 48, 50)	24.49 percentage of participants	40.82 percentage of participants	72.92 percentage of participants	10.00 percentage of participants
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 14 (n=38, 37, 37, 33)	23.68 percentage of participants	35.14 percentage of participants	56.76 percentage of participants	9.09 percentage of participants
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 4 (n=49, 49, 48, 50)	18.37 percentage of participants	28.57 percentage of participants	33.33 percentage of participants	4.00 percentage of participants
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 8 (n=49, 49, 48, 50)	24.49 percentage of participants	44.90 percentage of participants	56.25 percentage of participants	14.00 percentage of participants
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of "Clear" or "Almost Clear" Week 16 (n=37, 37, 41, 30)	24.32 percentage of participants	18.92 percentage of participants	41.46 percentage of participants	10.00 percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 14, 16

Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF for week 2, 4, 8 and no imputation done for week 14, 16. n=participants evaluable for this measure at specified time points for each arm group respectively.

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score Week 8 (n=48, 49, 48, 50)	20.83 percentage of participants	40.82 percentage of participants	62.50 percentage of participants	2.00 percentage of participants
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score Week 2 (n=47, 48, 48, 49)	0.00 percentage of participants	2.08 percentage of participants	2.08 percentage of participants	0.00 percentage of participants
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score Week 4 (n=48, 49, 48, 50)	8.33 percentage of participants	14.29 percentage of participants	20.83 percentage of participants	0.00 percentage of participants
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score Week 14 (n=38, 37, 37, 33)	23.68 percentage of participants	37.84 percentage of participants	59.46 percentage of participants	6.06 percentage of participants
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score Week 16 (n=37, 36, 41, 30)	24.32 percentage of participants	22.22 percentage of participants	39.02 percentage of participants	6.67 percentage of participants

SECONDARY outcome

Timeframe: Week 2, 4, 8, 12, 14, 16

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 2 (n=47, 48, 48, 49)	10.64 percentage of participants	14.58 percentage of participants	25.00 percentage of participants	0.00 percentage of participants
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 4 (n=48, 49, 48, 50)	29.17 percentage of participants	44.90 percentage of participants	62.50 percentage of participants	6.00 percentage of participants
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 8 (n=48, 49, 48, 50)	41.67 percentage of participants	55.10 percentage of participants	79.17 percentage of participants	14.00 percentage of participants
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 12 (n=48, 49, 48, 50)	39.58 percentage of participants	65.31 percentage of participants	87.50 percentage of participants	20.00 percentage of participants
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 14 (n=38, 37, 37, 33)	42.11 percentage of participants	59.46 percentage of participants	86.49 percentage of participants	24.24 percentage of participants
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score Week 16 (n=37, 36, 41, 30)	40.54 percentage of participants	47.22 percentage of participants	68.29 percentage of participants	23.33 percentage of participants

SECONDARY outcome

Timeframe: Week 12

Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF.

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score	14.58 percentage of participants	18.37 percentage of participants	33.33 percentage of participants	0.00 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Week 2, 4, 8, 12, 14, 16

Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. No imputation was done. n=participants evaluable for this measure at specified time points for each arm group respectively.

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Trunk Erythema (n=43, 40, 47, 39)	1.5 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.16	1.2 units on a scale Standard Error 0.16	2.3 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Head/Neck Induration (n=48, 49, 48, 50)	2.0 units on a scale Standard Error 0.14	1.8 units on a scale Standard Error 0.13	2.1 units on a scale Standard Error 0.15	2.0 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Trunk Induration (n=47, 47, 48, 46)	2.1 units on a scale Standard Error 0.15	1.7 units on a scale Standard Error 0.15	2.0 units on a scale Standard Error 0.13	2.4 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Lower Limbs Induration (n=38, 37, 37, 33)	1.9 units on a scale Standard Error 0.16	1.5 units on a scale Standard Error 0.17	1.3 units on a scale Standard Error 0.18	2.2 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Trunk Scaling (n=38, 37, 37, 33)	1.5 units on a scale Standard Error 0.18	1.3 units on a scale Standard Error 0.18	1.1 units on a scale Standard Error 0.18	1.8 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Upper Limbs Induration(n=47, 48, 48, 49)	2.0 units on a scale Standard Error 0.13	2.1 units on a scale Standard Error 0.12	1.9 units on a scale Standard Error 0.13	2.4 units on a scale Standard Error 0.10
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Lower Limbs Scaling (n=38, 39, 43, 34)	1.8 units on a scale Standard Error 0.18	1.4 units on a scale Standard Error 0.14	0.9 units on a scale Standard Error 0.13	2.3 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Head/Neck Scaling (n=38, 37, 37, 33)	1.2 units on a scale Standard Error 0.18	1.1 units on a scale Standard Error 0.19	0.9 units on a scale Standard Error 0.18	1.7 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Upper Limbs Scaling (n=38, 37, 37, 33)	1.8 units on a scale Standard Error 0.16	1.6 units on a scale Standard Error 0.15	1.3 units on a scale Standard Error 0.17	2.1 units on a scale Standard Error 0.17
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Head/Neck Erythema (n=48, 49, 48, 50)	2.1 units on a scale Standard Error 0.13	2.1 units on a scale Standard Error 0.14	2.4 units on a scale Standard Error 0.15	2.4 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Upper Limbs Erythema (n=48, 49, 48, 50)	2.8 units on a scale Standard Error 0.09	2.7 units on a scale Standard Error 0.11	2.8 units on a scale Standard Error 0.10	2.9 units on a scale Standard Error 0.07
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Trunk Erythema (n=48, 49, 48, 50)	2.6 units on a scale Standard Error 0.13	2.6 units on a scale Standard Error 0.14	2.9 units on a scale Standard Error 0.10	2.8 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Lower Limbs Erythema (n=48, 49, 48, 50)	3.0 units on a scale Standard Error 0.08	2.9 units on a scale Standard Error 0.11	3.0 units on a scale Standard Error 0.11	3.1 units on a scale Standard Error 0.08
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Head/Neck Erythema (n=47, 48, 48, 49)	1.8 units on a scale Standard Error 0.15	1.4 units on a scale Standard Error 0.14	1.4 units on a scale Standard Error 0.15	2.2 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Upper Limbs Erythema (n=47, 48, 48, 49)	2.2 units on a scale Standard Error 0.12	2.2 units on a scale Standard Error 0.13	2.0 units on a scale Standard Error 0.10	2.7 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Trunk Erythema (n=47, 48, 48, 49)	2.1 units on a scale Standard Error 0.14	2.0 units on a scale Standard Error 0.17	2.1 units on a scale Standard Error 0.14	2.7 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Lower Limbs Erythema (n=47, 48, 48, 49)	2.6 units on a scale Standard Error 0.11	2.4 units on a scale Standard Error 0.13	2.3 units on a scale Standard Error 0.14	2.9 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Head/Neck Erythema (n=47, 47, 48, 46)	1.5 units on a scale Standard Error 0.14	1.1 units on a scale Standard Error 0.15	1.0 units on a scale Standard Error 0.14	2.1 units on a scale Standard Error 0.15
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Upper Limbs Erythema (n=47, 47, 48, 46)	1.9 units on a scale Standard Error 0.13	1.7 units on a scale Standard Error 0.14	1.5 units on a scale Standard Error 0.09	2.5 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Trunk Erythema (n= 47, 47, 48, 46)	1.8 units on a scale Standard Error 0.15	1.7 units on a scale Standard Error 0.17	1.6 units on a scale Standard Error 0.13	2.5 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Lower Limbs Erythema (n= 47, 47, 48, 46)	2.3 units on a scale Standard Error 0.13	2.0 units on a scale Standard Error 0.15	1.8 units on a scale Standard Error 0.13	2.8 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Head/Neck Erythema (n=43, 40, 47, 39)	1.2 units on a scale Standard Error 0.15	0.8 units on a scale Standard Error 0.16	0.6 units on a scale Standard Error 0.13	1.8 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Upper Limbs Erythema (n=43, 40, 47, 39)	1.6 units on a scale Standard Error 0.15	1.4 units on a scale Standard Error 0.14	1.1 units on a scale Standard Error 0.12	2.3 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Lower Limbs Erythema (n=43, 40, 47, 39)	1.8 units on a scale Standard Error 0.14	1.4 units on a scale Standard Error 0.16	1.2 units on a scale Standard Error 0.14	2.5 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Head/Neck Erythema (n=38, 39, 43, 34)	1.1 units on a scale Standard Error 0.17	0.8 units on a scale Standard Error 0.15	0.4 units on a scale Standard Error 0.11	1.7 units on a scale Standard Error 0.19
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Upper Limbs Erythema (n=38, 39, 43, 34)	1.5 units on a scale Standard Error 0.17	1.3 units on a scale Standard Error 0.12	1.0 units on a scale Standard Error 0.12	2.3 units on a scale Standard Error 0.15
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Trunk Erythema (n=38, 39, 43, 34)	1.5 units on a scale Standard Error 0.18	1.1 units on a scale Standard Error 0.17	0.9 units on a scale Standard Error 0.16	2.4 units on a scale Standard Error 0.17
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Lower Limbs Erythema (n=38, 39, 43, 34)	1.8 units on a scale Standard Error 0.17	1.3 units on a scale Standard Error 0.13	1.2 units on a scale Standard Error 0.15	2.6 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Head/Neck Erythema (n=38, 37, 37, 33)	1.2 units on a scale Standard Error 0.18	1.1 units on a scale Standard Error 0.14	0.9 units on a scale Standard Error 0.17	1.7 units on a scale Standard Error 0.20
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Upper Limbs Erythema (n=38, 37, 37, 33)	1.8 units on a scale Standard Error 0.17	1.5 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.16	2.3 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Trunk Erythema (n=38, 37, 37, 33)	1.6 units on a scale Standard Error 0.19	1.4 units on a scale Standard Error 0.18	1.2 units on a scale Standard Error 0.20	2.4 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Lower Limbs Erythema (n=38, 37, 37, 33)	2.0 units on a scale Standard Error 0.17	1.6 units on a scale Standard Error 0.17	1.4 units on a scale Standard Error 0.18	2.6 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Head/Neck Erythema (n=37, 36, 41, 30)	1.3 units on a scale Standard Error 0.20	1.5 units on a scale Standard Error 0.16	1.0 units on a scale Standard Error 0.18	1.8 units on a scale Standard Error 0.22
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Upper Limbs Erythema (n=37, 36, 41, 30)	1.9 units on a scale Standard Error 0.21	1.8 units on a scale Standard Error 0.14	1.7 units on a scale Standard Error 0.15	2.3 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Trunk Erythema (n=37, 36, 41, 30)	1.8 units on a scale Standard Error 0.21	1.8 units on a scale Standard Error 0.17	1.8 units on a scale Standard Error 0.18	2.3 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Lower Limbs Erythema (n=37, 36, 41, 30)	2.2 units on a scale Standard Error 0.18	1.8 units on a scale Standard Error 0.15	1.7 units on a scale Standard Error 0.18	2.7 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Upper Limbs Induration(n=48, 49, 48, 50)	2.5 units on a scale Standard Error 0.11	2.6 units on a scale Standard Error 0.11	2.7 units on a scale Standard Error 0.11	2.5 units on a scale Standard Error 0.10
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Trunk Induration (n=48, 49, 48, 50)	2.4 units on a scale Standard Error 0.12	2.3 units on a scale Standard Error 0.12	2.6 units on a scale Standard Error 0.12	2.7 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Lower Limbs Induration(n=48, 49, 48, 50)	2.8 units on a scale Standard Error 0.09	2.7 units on a scale Standard Error 0.10	2.8 units on a scale Standard Error 0.12	2.7 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Head/Neck Induration (n=47, 48, 48, 49)	1.4 units on a scale Standard Error 0.15	1.4 units on a scale Standard Error 0.14	1.3 units on a scale Standard Error 0.15	1.9 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Lower Limbs Induration(n=47, 48, 48, 49)	2.5 units on a scale Standard Error 0.12	2.4 units on a scale Standard Error 0.12	2.1 units on a scale Standard Error 0.14	2.6 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Head/Neck Induration (n=47, 47, 48, 46)	1.2 units on a scale Standard Error 0.14	0.8 units on a scale Standard Error 0.13	0.8 units on a scale Standard Error 0.14	1.7 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Upper Limbs Induration (n=47, 47, 48, 46)	1.9 units on a scale Standard Error 0.13	1.7 units on a scale Standard Error 0.13	1.4 units on a scale Standard Error 0.14	2.2 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Trunk Induration (n=47, 47, 48, 46)	1.7 units on a scale Standard Error 0.15	1.5 units on a scale Standard Error 0.15	1.4 units on a scale Standard Error 0.14	2.3 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Lower Limbs Induration (n=47, 47, 48, 46)	2.2 units on a scale Standard Error 0.14	1.9 units on a scale Standard Error 0.13	1.6 units on a scale Standard Error 0.14	2.3 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Head/Neck Induration (n=43, 40, 47, 39)	1.0 units on a scale Standard Error 0.14	0.6 units on a scale Standard Error 0.14	0.5 units on a scale Standard Error 0.13	1.5 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Upper Limbs Induration (n=43, 40, 47, 39)	1.7 units on a scale Standard Error 0.16	1.4 units on a scale Standard Error 0.14	1.2 units on a scale Standard Error 0.15	2.2 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Trunk Induration (n=43, 40, 47, 39)	1.5 units on a scale Standard Error 0.17	1.1 units on a scale Standard Error 0.17	1.1 units on a scale Standard Error 0.16	2.0 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Lower Limbs Induration (n=43, 40, 47, 39)	1.8 units on a scale Standard Error 0.17	1.3 units on a scale Standard Error 0.15	1.2 units on a scale Standard Error 0.16	2.2 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Head/Neck Induration (n=38, 39, 43, 34)	1.0 units on a scale Standard Error 0.17	0.5 units on a scale Standard Error 0.12	0.3 units on a scale Standard Error 0.10	1.5 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Upper Limbs Induration (n=38, 37, 37, 33)	1.4 units on a scale Standard Error 0.17	1.2 units on a scale Standard Error 0.12	1.0 units on a scale Standard Error 0.14	2.0 units on a scale Standard Error 0.16
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Trunk Induration (n=38, 39, 43, 34)	1.4 units on a scale Standard Error 0.18	0.9 units on a scale Standard Error 0.16	0.8 units on a scale Standard Error 0.15	2.0 units on a scale Standard Error 0.17
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Lower limbs induration (n=38, 39, 43, 34)	1.7 units on a scale Standard Error 0.17	1.2 units on a scale Standard Error 0.14	1.0 units on a scale Standard Error 0.14	2.2 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Head/Neck Induration (n=38, 37, 37, 33)	1.0 units on a scale Standard Error 0.16	0.9 units on a scale Standard Error 0.15	0.7 units on a scale Standard Error 0.16	1.4 units on a scale Standard Error 0.17
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Upper Limbs Induration (n=38, 37, 37, 33)	1.8 units on a scale Standard Error 0.18	1.4 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.16	2.1 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Trunk Induration (n=38, 37, 37, 33)	1.4 units on a scale Standard Error 0.18	1.3 units on a scale Standard Error 0.18	1.1 units on a scale Standard Error 0.18	1.9 units on a scale Standard Error 0.17
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Head/Neck Induration (n=37, 36, 41, 30)	1.1 units on a scale Standard Error 0.18	1.2 units on a scale Standard Error 0.17	0.8 units on a scale Standard Error 0.15	1.6 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Upper Limbs Induration (n=37, 36, 41, 30)	1.8 units on a scale Standard Error 0.20	1.9 units on a scale Standard Error 0.16	1.5 units on a scale Standard Error 0.16	2.2 units on a scale Standard Error 0.15
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Trunk Induration (n=37, 36, 41, 30)	1.5 units on a scale Standard Error 0.20	1.6 units on a scale Standard Error 0.18	1.5 units on a scale Standard Error 0.17	2.1 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Lower Limbs Induration (n=37, 36, 41, 30)	1.9 units on a scale Standard Error 0.19	1.8 units on a scale Standard Error 0.15	1.4 units on a scale Standard Error 0.17	2.4 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: Lower Limbs Scaling (n=38, 37, 37, 33)	1.9 units on a scale Standard Error 0.18	1.5 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.20	2.2 units on a scale Standard Error 0.19
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Head/Neck Scaling (n=48, 49, 48, 50)	2.1 units on a scale Standard Error 0.16	2.2 units on a scale Standard Error 0.13	2.3 units on a scale Standard Error 0.14	2.2 units on a scale Standard Error 0.14
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Upper Limbs Scaling (n=48, 49, 48, 50)	2.5 units on a scale Standard Error 0.10	2.8 units on a scale Standard Error 0.11	2.6 units on a scale Standard Error 0.09	2.6 units on a scale Standard Error 0.10
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Trunk Scaling (n=48, 49, 48, 50)	2.4 units on a scale Standard Error 0.14	2.4 units on a scale Standard Error 0.14	2.5 units on a scale Standard Error 0.12	2.6 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: Lower Limbs Scaling (n=48, 49, 48, 50)	3.1 units on a scale Standard Error 0.10	2.9 units on a scale Standard Error 0.11	2.7 units on a scale Standard Error 0.12	2.9 units on a scale Standard Error 0.09
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Head/Neck Scaling (n=47, 48, 48, 49)	1.7 units on a scale Standard Error 0.16	1.6 units on a scale Standard Error 0.16	1.4 units on a scale Standard Error 0.16	1.9 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Upper Limbs Scaling (n=48, 49, 48, 50)	2.1 units on a scale Standard Error 0.13	2.2 units on a scale Standard Error 0.13	2.0 units on a scale Standard Error 0.12	2.4 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Trunk Scaling (n=47, 48, 48, 49)	2.1 units on a scale Standard Error 0.14	1.8 units on a scale Standard Error 0.16	1.9 units on a scale Standard Error 0.12	2.3 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: Lower Limbs Scaling (n=47, 48, 48, 49)	2.6 units on a scale Standard Error 0.12	2.5 units on a scale Standard Error 0.14	2.1 units on a scale Standard Error 0.13	2.7 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Head/Neck Scaling (n=47, 47, 48, 46)	1.5 units on a scale Standard Error 0.16	1.1 units on a scale Standard Error 0.15	0.9 units on a scale Standard Error 0.14	1.8 units on a scale Standard Error 0.16
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Upper Limbs Scaling (n=47, 47, 48, 46)	2.0 units on a scale Standard Error 0.12	1.9 units on a scale Standard Error 0.16	1.6 units on a scale Standard Error 0.14	2.3 units on a scale Standard Error 0.11
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Trunk Scaling (n=47, 47, 48, 46)	1.8 units on a scale Standard Error 0.15	1.5 units on a scale Standard Error 0.16	1.4 units on a scale Standard Error 0.12	2.4 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: Lower Limbs Scaling (n=47, 47, 48, 46)	2.4 units on a scale Standard Error 0.11	2.0 units on a scale Standard Error 0.15	1.8 units on a scale Standard Error 0.14	2.5 units on a scale Standard Error 0.12
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Head/Neck Scaling (n=43, 40, 47, 39)	1.2 units on a scale Standard Error 0.15	0.8 units on a scale Standard Error 0.16	0.7 units on a scale Standard Error 0.14	1.6 units on a scale Standard Error 0.16
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Upper Limbs Scaling (n=43, 40, 47, 39)	1.7 units on a scale Standard Error 0.14	1.5 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.14	2.2 units on a scale Standard Error 0.15
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Trunk Scaling (n=43, 40, 47, 39)	1.4 units on a scale Standard Error 0.16	1.2 units on a scale Standard Error 0.19	1.0 units on a scale Standard Error 0.14	2.1 units on a scale Standard Error 0.13
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: Lower Limbs Scaling (n=43, 40, 47, 39)	1.9 units on a scale Standard Error 0.16	1.5 units on a scale Standard Error 0.16	1.3 units on a scale Standard Error 0.15	2.4 units on a scale Standard Error 0.15
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Head/Neck Scaling (n=38, 39, 43, 34)	1.0 units on a scale Standard Error 0.17	0.8 units on a scale Standard Error 0.14	0.5 units on a scale Standard Error 0.12	1.6 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Upper Limbs Scaling (n=38, 39, 43, 34)	1.5 units on a scale Standard Error 0.16	1.4 units on a scale Standard Error 0.13	1.1 units on a scale Standard Error 0.14	2.0 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: Trunk Scaling (n=38, 39, 43, 34)	1.3 units on a scale Standard Error 0.18	1.0 units on a scale Standard Error 0.18	0.7 units on a scale Standard Error 0.12	1.9 units on a scale Standard Error 0.19
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Head/Neck Scaling (n=37, 36, 41, 30)	1.2 units on a scale Standard Error 0.19	1.6 units on a scale Standard Error 0.20	1.0 units on a scale Standard Error 0.17	1.7 units on a scale Standard Error 0.22
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Upper Limbs Scaling (n=37, 36, 41, 30)	1.9 units on a scale Standard Error 0.19	1.7 units on a scale Standard Error 0.16	1.7 units on a scale Standard Error 0.16	2.3 units on a scale Standard Error 0.18
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Trunk Scaling (n=37, 36, 41, 30)	1.7 units on a scale Standard Error 0.20	1.5 units on a scale Standard Error 0.18	1.4 units on a scale Standard Error 0.16	2.0 units on a scale Standard Error 0.20
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: Lower Limbs Scaling (n=37, 36, 41, 30)	2.2 units on a scale Standard Error 0.19	1.8 units on a scale Standard Error 0.17	1.5 units on a scale Standard Error 0.17	2.4 units on a scale Standard Error 0.19
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Baseline: PASI Total Score	21.5 units on a scale Standard Error 0.97	21.2 units on a scale Standard Error 1.15	22.6 units on a scale Standard Error 1.49	21.5 units on a scale Standard Error 1.01
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 2: PASI Total Score	17.0 units on a scale Standard Error 0.97	16.3 units on a scale Standard Error 1.39	15.3 units on a scale Standard Error 1.27	20.4 units on a scale Standard Error 1.23
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 4: PASI Total Score	14.0 units on a scale Standard Error 0.98	12.3 units on a scale Standard Error 1.46	10.4 units on a scale Standard Error 1.13	19.1 units on a scale Standard Error 1.50
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 8: PASI Total Score	10.7 units on a scale Standard Error 1.02	8.1 units on a scale Standard Error 1.45	6.9 units on a scale Standard Error 1.14	17.3 units on a scale Standard Error 1.31
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 12: PASI Total Score	9.6 units on a scale Standard Error 1.18	5.7 units on a scale Standard Error 0.73	5.0 units on a scale Standard Error 0.87	15.8 units on a scale Standard Error 1.30
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 14: PASI Total Score	10.8 units on a scale Standard Error 1.18	7.6 units on a scale Standard Error 1.06	6.7 units on a scale Standard Error 1.37	16.1 units on a scale Standard Error 1.39
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score Week 16: PASI Total Score	11.9 units on a scale Standard Error 1.33	9.1 units on a scale Standard Error 0.91	8.8 units on a scale Standard Error 1.26	16.4 units on a scale Standard Error 1.66

SECONDARY outcome

Timeframe: Baseline, Week 2, 4, 8, 12, 14, 16

Outcome measures

Outcome measures
Measure	CP-690,550 2 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 Participants CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=48 Participants CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 Participants Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Head/Neck Erythema (n=38, 37, 37, 33)	-1.0 units on a scale Standard Error 0.18	-1.0 units on a scale Standard Error 0.19	-1.5 units on a scale Standard Error 0.21	-0.6 units on a scale Standard Error 0.19
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Upper Limbs Erythema (n=38, 37, 37, 33)	-1.1 units on a scale Standard Error 0.17	-1.0 units on a scale Standard Error 0.17	-1.5 units on a scale Standard Error 0.18	-0.7 units on a scale Standard Error 0.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Lower Limbs Erythema (n=38, 37, 37, 33)	-1.1 units on a scale Standard Error 0.16	-1.2 units on a scale Standard Error 0.17	-1.6 units on a scale Standard Error 0.20	-0.4 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Head/Neck Erythema (n=37, 36, 41, 30)	-0.9 units on a scale Standard Error 0.19	-0.5 units on a scale Standard Error 0.18	-1.3 units on a scale Standard Error 0.21	-0.5 units on a scale Standard Error 0.22
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Trunk Erythema (n=37, 36, 41, 30)	-0.9 units on a scale Standard Error 0.22	-0.6 units on a scale Standard Error 0.17	-1.1 units on a scale Standard Error 0.20	-0.6 units on a scale Standard Error 0.19
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Upper Limbs Induration (n=47, 48, 48, 49)	-0.5 units on a scale Standard Error 0.09	-0.5 units on a scale Standard Error 0.08	-0.8 units on a scale Standard Error 0.11	-0.1 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Trunk Scaling (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.19	-1.4 units on a scale Standard Error 0.17	-1.8 units on a scale Standard Error 0.16	-0.7 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Trunk Induration (n=47, 48, 48, 49)	-0.4 units on a scale Standard Error 0.10	-0.6 units on a scale Standard Error 0.11	-0.6 units on a scale Standard Error 0.11	-0.3 units on a scale Standard Error 0.07
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Lower Limbs Induration (n=47, 48, 48, 49)	-0.3 units on a scale Standard Error 0.08	-0.4 units on a scale Standard Error 0.08	-0.7 units on a scale Standard Error 0.12	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Upper Limbs Induration (n=47, 47, 48, 46)	-0.6 units on a scale Standard Error 0.12	-0.8 units on a scale Standard Error 0.12	-1.3 units on a scale Standard Error 0.13	-0.3 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Trunk Induration (n=47, 47, 48, 46)	-0.8 units on a scale Standard Error 0.12	-0.7 units on a scale Standard Error 0.13	-1.2 units on a scale Standard Error 0.12	-0.4 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Upper Limbs Induration (n=43, 40, 47, 39)	-0.9 units on a scale Standard Error 0.15	-1.1 units on a scale Standard Error 0.13	-1.5 units on a scale Standard Error 0.16	-0.3 units on a scale Standard Error 0.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Lower Limbs Induration (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.15	-1.3 units on a scale Standard Error 0.16	-1.6 units on a scale Standard Error 0.17	-0.5 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Trunk Induration (n=38, 39, 43, 34)	-1.1 units on a scale Standard Error 0.18	-1.2 units on a scale Standard Error 0.14	-1.8 units on a scale Standard Error 0.16	-0.7 units on a scale Standard Error 0.15
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Lower Limbs Induration (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.15	-1.7 units on a scale Standard Error 0.15	-0.5 units on a scale Standard Error 0.11
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Head/Neck Induration (n=38, 37, 37, 33)	-1.1 units on a scale Standard Error 0.15	-0.8 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.20	-0.5 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Upper Limbs Induration (n=38, 37, 37, 33)	-0.8 units on a scale Standard Error 0.15	-1.0 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.18	-0.5 units on a scale Standard Error 0.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Trunk Induration (n=38, 37, 37, 33)	-1.0 units on a scale Standard Error 0.18	-0.9 units on a scale Standard Error 0.15	-1.5 units on a scale Standard Error 0.20	-0.7 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Head/Neck Induration (n=37, 36, 41, 30)	-1.1 units on a scale Standard Error 0.15	-0.4 units on a scale Standard Error 0.18	-1.3 units on a scale Standard Error 0.20	-0.3 units on a scale Standard Error 0.19
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Upper Limbs Induration (n=37, 36, 41, 30)	-0.8 units on a scale Standard Error 0.17	-0.6 units on a scale Standard Error 0.16	-1.2 units on a scale Standard Error 0.18	-0.4 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Trunk Scaling (n=47, 47, 48, 46)	-0.6 units on a scale Standard Error 0.13	-0.9 units on a scale Standard Error 0.13	-1.1 units on a scale Standard Error 0.14	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Upper Limbs Scaling (n=43, 40, 47, 39)	-0.8 units on a scale Standard Error 0.16	-1.2 units on a scale Standard Error 0.13	-1.3 units on a scale Standard Error 0.16	-0.4 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Trunk Scaling (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.18	-1.2 units on a scale Standard Error 0.16	-1.5 units on a scale Standard Error 0.17	-0.5 units on a scale Standard Error 0.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Lower Limbs Scaling (n=43, 40, 47, 39)	-1.1 units on a scale Standard Error 0.14	-1.3 units on a scale Standard Error 0.15	-1.4 units on a scale Standard Error 0.15	-0.5 units on a scale Standard Error 0.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Head/Neck Scaling (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.19	-1.4 units on a scale Standard Error 0.19	-1.8 units on a scale Standard Error 0.18	-0.3 units on a scale Standard Error 0.20
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Upper Limbs Scaling (n=38, 39, 43, 34)	-1.0 units on a scale Standard Error 0.18	-1.3 units on a scale Standard Error 0.14	-1.5 units on a scale Standard Error 0.17	-0.6 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Lower Limbs Scaling (n=38, 39, 43, 34)	-1.3 units on a scale Standard Error 0.15	-1.4 units on a scale Standard Error 0.15	-1.7 units on a scale Standard Error 0.15	-0.6 units on a scale Standard Error 0.15
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Head/Neck Scaling (n=38, 37, 37, 33)	-1.0 units on a scale Standard Error 0.19	-1.0 units on a scale Standard Error 0.19	-1.4 units on a scale Standard Error 0.20	-0.3 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Trunk Scaling (n=38, 37, 37, 33)	-0.8 units on a scale Standard Error 0.18	-1.0 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.20	-0.8 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Lower Limbs Scaling (n=38, 37, 37, 33)	-1.2 units on a scale Standard Error 0.17	-1.2 units on a scale Standard Error 0.17	-1.4 units on a scale Standard Error 0.19	-0.7 units on a scale Standard Error 0.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Head/Neck Scaling (n=37, 36, 41, 30)	-1.0 units on a scale Standard Error 0.18	-0.5 units on a scale Standard Error 0.18	-1.4 units on a scale Standard Error 0.20	-0.2 units on a scale Standard Error 0.22
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Trunk Scaling (n=37, 36, 41, 30)	-0.8 units on a scale Standard Error 0.20	-0.8 units on a scale Standard Error 0.15	-1.2 units on a scale Standard Error 0.19	-0.7 units on a scale Standard Error 0.19
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: PASI Total Score (n=47, 48, 48, 49)	-4.7 units on a scale Standard Error 0.81	-4.7 units on a scale Standard Error 0.62	-7.3 units on a scale Standard Error 0.86	-0.8 units on a scale Standard Error 0.69
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: PASI Total Score (n=47, 47, 48, 46)	-7.5 units on a scale Standard Error 1.05	-8.6 units on a scale Standard Error 0.93	-12.2 units on a scale Standard Error 1.18	-2.7 units on a scale Standard Error 0.86
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: PASI Total Score (n=43, 40, 47, 39)	-10.9 units on a scale Standard Error 1.41	-11.6 units on a scale Standard Error 1.09	-15.8 units on a scale Standard Error 1.38	-3.7 units on a scale Standard Error 0.96
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: PASI Total Score (n=38, 39, 43, 34)	-12.1 units on a scale Standard Error 1.59	-13.1 units on a scale Standard Error 1.05	-17.9 units on a scale Standard Error 1.59	-5.1 units on a scale Standard Error 1.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: PASI Total Score (n=38, 37, 37, 33)	-10.9 units on a scale Standard Error 1.58	-11.4 units on a scale Standard Error 1.13	-16.5 units on a scale Standard Error 1.95	-4.4 units on a scale Standard Error 1.32
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Head/Neck Erythema (n=47, 48, 48, 49)	-0.4 units on a scale Standard Error 0.10	-0.7 units on a scale Standard Error 0.13	-1.0 units on a scale Standard Error 0.15	-0.2 units on a scale Standard Error 0.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Upper Limbs Erythema (n=47, 48, 48, 49)	-0.6 units on a scale Standard Error 0.11	-0.5 units on a scale Standard Error 0.09	-0.8 units on a scale Standard Error 0.10	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Trunk Erythema (n=47, 48, 48, 49)	-0.6 units on a scale Standard Error 0.12	-0.6 units on a scale Standard Error 0.12	-0.8 units on a scale Standard Error 0.13	-0.2 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Lower Limbs Erythema (n=47, 48, 48, 49)	-0.4 units on a scale Standard Error 0.11	-0.6 units on a scale Standard Error 0.11	-0.8 units on a scale Standard Error 0.11	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Head/Neck Erythema (n=47, 47, 48, 46)	-0.7 units on a scale Standard Error 0.13	-1.0 units on a scale Standard Error 0.15	-1.4 units on a scale Standard Error 0.16	-0.3 units on a scale Standard Error 0.15
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Upper Limbs Erythema (n=47, 47, 48, 46)	-0.9 units on a scale Standard Error 0.14	-1.0 units on a scale Standard Error 0.11	-1.3 units on a scale Standard Error 0.12	-0.5 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Trunk Erythema (n=47, 47, 48, 46)	-0.9 units on a scale Standard Error 0.14	-0.8 units on a scale Standard Error 0.12	-1.3 units on a scale Standard Error 0.12	-0.4 units on a scale Standard Error 0.07
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Lower Limbs Erythema (n=47, 47, 48, 46)	-0.7 units on a scale Standard Error 0.13	-0.9 units on a scale Standard Error 0.11	-1.3 units on a scale Standard Error 0.12	-0.4 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Head/Neck Erythema (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.14	-1.3 units on a scale Standard Error 0.19	-1.7 units on a scale Standard Error 0.18	-0.6 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Upper Limbs Erythema (n=43, 40, 47, 39)	-1.2 units on a scale Standard Error 0.16	-1.2 units on a scale Standard Error 0.14	-1.7 units on a scale Standard Error 0.14	-0.6 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Trunk Erythema (n=43, 40, 47, 39)	-1.1 units on a scale Standard Error 0.18	-1.2 units on a scale Standard Error 0.15	-1.7 units on a scale Standard Error 0.17	-0.5 units on a scale Standard Error 0.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Lower Limbs Erythema (n=43, 40, 47, 39)	-1.1 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.16	-1.8 units on a scale Standard Error 0.16	-0.5 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Head/Neck Erythema (n=38, 39, 43, 34)	-1.1 units on a scale Standard Error 0.17	-1.2 units on a scale Standard Error 0.18	-2.0 units on a scale Standard Error 0.19	-0.6 units on a scale Standard Error 0.20
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Upper Limbs Erythema (n=38, 39, 43, 34)	-1.3 units on a scale Standard Error 0.17	-1.3 units on a scale Standard Error 0.14	-1.8 units on a scale Standard Error 0.15	-0.7 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Trunk Erythema (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.20	-1.3 units on a scale Standard Error 0.19	-1.9 units on a scale Standard Error 0.18	-0.5 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Lower Limbs Erythema (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.18	-1.5 units on a scale Standard Error 0.14	-1.9 units on a scale Standard Error 0.17	-0.4 units on a scale Standard Error 0.12
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Trunk Erythema (n=38, 37, 37, 33)	-1.1 units on a scale Standard Error 0.19	-1.0 units on a scale Standard Error 0.20	-1.6 units on a scale Standard Error 0.20	-0.5 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Upper Limbs Erythema (n=37, 36, 41, 30)	-0.8 units on a scale Standard Error 0.19	-0.7 units on a scale Standard Error 0.16	-1.0 units on a scale Standard Error 0.17	-0.6 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Lower Limbs Erythema (n=37, 36, 41, 30)	-0.7 units on a scale Standard Error 0.18	-1.0 units on a scale Standard Error 0.18	-1.3 units on a scale Standard Error 0.18	-0.4 units on a scale Standard Error 0.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Head/Neck Induration (n=47, 48, 48, 49)	-0.6 units on a scale Standard Error 0.11	-0.4 units on a scale Standard Error 0.11	-0.8 units on a scale Standard Error 0.13	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Head/Neck Induration (n=47, 47, 48, 46)	-0.8 units on a scale Standard Error 0.11	-0.9 units on a scale Standard Error 0.13	-1.3 units on a scale Standard Error 0.16	-0.3 units on a scale Standard Error 0.15
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Lower Limbs Induration (n=47, 47, 48, 46)	-0.6 units on a scale Standard Error 0.12	-0.8 units on a scale Standard Error 0.12	-1.2 units on a scale Standard Error 0.13	-0.5 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Head/Neck Induration (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.13	-1.1 units on a scale Standard Error 0.16	-1.5 units on a scale Standard Error 0.18	-0.5 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Trunk Induration (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.16	-1.1 units on a scale Standard Error 0.16	-1.5 units on a scale Standard Error 0.15	-0.6 units on a scale Standard Error 0.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Head/Neck Induration (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.16	-1.2 units on a scale Standard Error 0.15	-1.7 units on a scale Standard Error 0.18	-0.4 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 12: Upper Limbs Induration (n=38, 39, 43, 34)	-1.2 units on a scale Standard Error 0.15	-1.2 units on a scale Standard Error 0.13	-1.6 units on a scale Standard Error 0.17	-0.5 units on a scale Standard Error 0.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Lower Limbs Induration (n=38, 37, 37, 33)	-1.1 units on a scale Standard Error 0.16	-1.1 units on a scale Standard Error 0.18	-1.4 units on a scale Standard Error 0.20	-0.5 units on a scale Standard Error 0.13
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Trunk Induration (n=37, 36, 41, 30)	-0.9 units on a scale Standard Error 0.20	-0.6 units on a scale Standard Error 0.14	-1.1 units on a scale Standard Error 0.19	-0.6 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Lower Limbs Induration (n=37, 36, 41, 30)	-1.0 units on a scale Standard Error 0.19	-0.8 units on a scale Standard Error 0.16	-1.4 units on a scale Standard Error 0.18	-0.4 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Head/Neck Scaling (n=47, 48, 48, 49)	-0.5 units on a scale Standard Error 0.12	-0.6 units on a scale Standard Error 0.13	-0.9 units on a scale Standard Error 0.13	-0.3 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Upper Limbs Scaling (n=47, 48, 48, 49)	-0.4 units on a scale Standard Error 0.10	-0.6 units on a scale Standard Error 0.10	-0.6 units on a scale Standard Error 0.10	-0.2 units on a scale Standard Error 0.08
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Trunk Scaling (n=47, 48, 48, 49)	-0.3 units on a scale Standard Error 0.12	-0.6 units on a scale Standard Error 0.13	-0.7 units on a scale Standard Error 0.11	-0.2 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 2: Lower Limbs Scaling (n=47, 48, 48, 49)	-0.4 units on a scale Standard Error 0.10	-0.4 units on a scale Standard Error 0.09	-0.6 units on a scale Standard Error 0.11	-0.2 units on a scale Standard Error 0.09
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Head/Neck Scaling (n=47, 47, 48, 46)	-0.7 units on a scale Standard Error 0.14	-1.0 units on a scale Standard Error 0.15	-1.4 units on a scale Standard Error 0.15	-0.4 units on a scale Standard Error 0.14
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Upper Limbs Scaling (n=47, 47, 48, 46)	-0.5 units on a scale Standard Error 0.14	-0.8 units on a scale Standard Error 0.12	-1.0 units on a scale Standard Error 0.13	-0.3 units on a scale Standard Error 0.10
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 4: Lower Limbs Scaling (n=47, 47, 48, 46)	-0.7 units on a scale Standard Error 0.09	-0.9 units on a scale Standard Error 0.12	-0.9 units on a scale Standard Error 0.14	-0.4 units on a scale Standard Error 0.11
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 8: Head/Neck Scaling (n=43, 40, 47, 39)	-1.0 units on a scale Standard Error 0.19	-1.4 units on a scale Standard Error 0.19	-1.6 units on a scale Standard Error 0.18	-0.4 units on a scale Standard Error 0.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 14: Upper Limbs Scaling (n=38, 37, 37, 33)	-0.7 units on a scale Standard Error 0.16	-1.1 units on a scale Standard Error 0.17	-1.3 units on a scale Standard Error 0.18	-0.6 units on a scale Standard Error 0.16
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Upper Limbs Scaling (n=37, 36, 41, 30)	-0.7 units on a scale Standard Error 0.16	-1.0 units on a scale Standard Error 0.14	-1.0 units on a scale Standard Error 0.16	-0.5 units on a scale Standard Error 0.18
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: Lower Limbs Scaling (n=37, 36, 41, 30)	-0.9 units on a scale Standard Error 0.16	-0.9 units on a scale Standard Error 0.18	-1.2 units on a scale Standard Error 0.19	-0.6 units on a scale Standard Error 0.17
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 Week 16: PASI Total Score (n=37, 36, 41, 30)	-9.7 units on a scale Standard Error 1.57	-9.3 units on a scale Standard Error 1.09	-14.0 units on a scale Standard Error 1.77	-5.1 units on a scale Standard Error 1.42

Adverse Events

CP-690,550 2 mg

Serious events: 2 serious events

Other events: 25 other events

Deaths: 0 deaths

CP-690,550 5 mg

Serious events: 1 serious events

Other events: 28 other events

Deaths: 0 deaths

CP-690,550 15 mg

Serious events: 0 serious events

Other events: 30 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 30 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	CP-690,550 2 mg n=49 participants at risk CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks.	CP-690,550 5 mg n=49 participants at risk CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks.	CP-690,550 15 mg n=49 participants at risk CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks.	Placebo n=50 participants at risk Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks.
Cardiac disorders Angina pectoris	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Cardiac disorders Atrial fibrillation	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Pyelonephritis	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Urinary tract infection	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Urosepsis	2.0% 1/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/49 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Other adverse events

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER